{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:04:27Z","timestamp":1760144667085,"version":"build-2065373602"},"reference-count":92,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","onlinecjc.ca","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1016\/j.cjca.2013.04.017","type":"journal-article","created":{"date-parts":[[2013,6,21]],"date-time":"2013-06-21T00:04:10Z","timestamp":1371773050000},"page":"779-785","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pharmacogenomics and Heart Failure in Congenital Heart Disease"],"prefix":"10.1016","volume":"29","author":[{"given":"Simon","family":"de Denus","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul F.","family":"Kantor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjca.2013.04.017_bib1","doi-asserted-by":"crossref","first-page":"749","DOI":"10.7326\/0003-4819-145-10-200611210-00007","article-title":"Pharmacogenomics: challenges and opportunities","volume":"145","author":"Roden","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cjca.2013.04.017_bib2","series-title":"Clinical Approach to Sudden Cardiac Death Syndromes","first-page":"273","article-title":"Pharmacogenomics","author":"de Denus","year":"2010"},{"key":"10.1016\/j.cjca.2013.04.017_bib3","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2217\/pgs.12.206","article-title":"Pharmacogenetics of ACE inhibitor-induced angioedema and cough: a systematic review and meta-analysis","volume":"14","author":"Mahmoudpour","year":"2013","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.cjca.2013.04.017_bib4","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1093\/eurheartj\/ehq032","article-title":"Mortality in adult congenital heart disease","volume":"31","author":"Verheugt","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2013.04.017_bib5","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/bdra.20764","article-title":"Association of common variants in ERBB4 with congenital left ventricular outflow tract obstruction defects","volume":"91","author":"McBride","year":"2011","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"key":"10.1016\/j.cjca.2013.04.017_bib6","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1161\/CIRCGENETICS.111.962035","article-title":"A\u00a0common variant in the PTPN11 gene contributes to the risk of tetralogy of Fallot","volume":"5","author":"Goodship","year":"2012","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.cjca.2013.04.017_bib7","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa052948","article-title":"Association of parental heart failure with risk of heart failure in offspring","volume":"355","author":"Lee","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2013.04.017_bib8","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/HCO.0b013e3280d9e855","article-title":"The contribution of familial and heritable risks in heart failure","volume":"22","author":"Abdel-Qadir","year":"2007","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.cjca.2013.04.017_bib9","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1161\/01.HYP.0000258554.87444.91","article-title":"Clinical and genetic correlates of aldosterone-to-renin ratio and relations to blood pressure in a community sample","volume":"49","author":"Newton-Cheh","year":"2007","journal-title":"Hypertension"},{"key":"10.1016\/j.cjca.2013.04.017_bib10","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1161\/01.HYP.30.5.1025","article-title":"Heritability of left ventricular mass: the Framingham Heart Study","volume":"30","author":"Post","year":"1997","journal-title":"Hypertension"},{"key":"10.1016\/j.cjca.2013.04.017_bib11","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1161\/01.HYP.0000244543.91937.79","article-title":"Circulating activities of angiotensin-converting enzyme, its homolog, angiotensin-converting enzyme 2, and neprilysin in a family study","volume":"48","author":"Rice","year":"2006","journal-title":"Hypertension"},{"key":"10.1016\/j.cjca.2013.04.017_bib12","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/sj.jhh.1001410","article-title":"Heritability of plasma renin activity and plasma concentration of angiotensinogen and angiotensin-converting enzyme","volume":"16","author":"Vinck","year":"2002","journal-title":"J\u00a0Hum Hypertens"},{"key":"10.1016\/j.cjca.2013.04.017_bib13","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1161\/01.CIR.0000081657.83724.A7","article-title":"Heritability and genetic linkage of plasma natriuretic peptide levels","volume":"108","author":"Wang","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2013.04.017_bib14","series-title":"Acute Coronary Syndromes. A companion to Braunwald's Heart Disease","first-page":"81","article-title":"Pharmacogenomics","author":"de Denus","year":"2011"},{"key":"10.1016\/j.cjca.2013.04.017_bib15","doi-asserted-by":"crossref","first-page":"511","DOI":"10.2217\/pgs.12.23","article-title":"Genome and exome sequencing in the clinic: unbiased genomic approaches with a high diagnostic yield","volume":"13","author":"Nelen","year":"2012","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.cjca.2013.04.017_bib16","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1056\/NEJMoa0706135","article-title":"HLA-B*5701 screening for hypersensitivity to abacavir","volume":"358","author":"Mallal","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2013.04.017_bib17","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1200\/JCO.2009.21.9170","article-title":"American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy","volume":"27","author":"Allegra","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cjca.2013.04.017_bib18","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/nature05911","article-title":"Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls","volume":"447","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.cjca.2013.04.017_bib19","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1161\/CIR.0b013e318256f1e0","volume":"126","author":"Jneid","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2013.04.017_bib20","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S1470-2045(10)70097-8","article-title":"Clinical implementation of pharmacogenomics: overcoming genetic exceptionalism","volume":"11","author":"Relling","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cjca.2013.04.017_bib21","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2217\/pgs.12.197","article-title":"An evaluation of pharmacists' expectations towards pharmacogenomics","volume":"14","author":"de Denus","year":"2013","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.cjca.2013.04.017_bib22","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/clpt.2010.279","article-title":"CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network","volume":"89","author":"Relling","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cjca.2013.04.017_bib23","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMra032424","article-title":"Drug metabolism and variability among patients in drug response","volume":"352","author":"Wilkinson","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2013.04.017_bib24","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1365-2710.2006.00699.x","article-title":"The relevance of CYP2D6 genetic polymorphism on chronic metoprolol therapy in cardiovascular patients","volume":"31","author":"Ismail","year":"2006","journal-title":"J\u00a0Clin Pharmacy Ther"},{"key":"10.1016\/j.cjca.2013.04.017_bib25","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa0809171","article-title":"Cytochrome p-450 polymorphisms and response to clopidogrel","volume":"360","author":"Mega","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2013.04.017_bib26","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1056\/NEJMoa0708078","article-title":"Genetic determinants of response to warfarin during initial anticoagulation","volume":"358","author":"Schwarz","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2013.04.017_bib27","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1034\/j.1600-6143.2003.00077.x","article-title":"Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms","volume":"3","author":"Zheng","year":"2003","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cjca.2013.04.017_bib28","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.healun.2010.09.015","article-title":"Association between renal function and CYP3A5 genotype in heart transplant recipients treated with calcineurin inhibitors","volume":"30","author":"de Denus","year":"2011","journal-title":"J\u00a0Heart Lung Transplant"},{"key":"10.1016\/j.cjca.2013.04.017_bib29","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/FPC.0b013e3282f70458","article-title":"Common ATP-binding cassette B1 variants are associated with increased digoxin serum concentration","volume":"18","author":"Aarnoudse","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.cjca.2013.04.017_bib30","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/sj.tpj.6500417","article-title":"Pharmacogenetics of warfarin: current status and future challenges","volume":"7","author":"Wadelius","year":"2007","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.cjca.2013.04.017_bib31","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/clpt.2008.10","article-title":"Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin","volume":"84","author":"Gage","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cjca.2013.04.017_bib32","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/clpt.2011.185","article-title":"Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing","volume":"90","author":"Johnson","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cjca.2013.04.017_bib33","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/S0002-8703(99)70226-7","article-title":"Angiotensinogen M235T polymorphism is associated with plasma angiotensinogen and cardiovascular disease","volume":"137","author":"Winkelmann","year":"1999","journal-title":"Am Heart J"},{"key":"10.1016\/j.cjca.2013.04.017_bib34","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.ahj.2004.05.020","article-title":"Impact of angiotensin-converting enzyme gene polymorphism on neurohormonal responses to high- versus low-dose enalapril in advanced heart failure","volume":"148","author":"Tang","year":"2004","journal-title":"Am Heart J"},{"key":"10.1016\/j.cjca.2013.04.017_bib35","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1016\/S0735-1097(01)01237-2","article-title":"Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype","volume":"37","author":"Cicoira","year":"2001","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2013.04.017_bib36","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1161\/01.CIR.0000031735.86021.79","article-title":"Angiotensin-converting enzyme genotype modulates pulmonary function and exercise capacity in treated patients with congestive stable heart failure","volume":"106","author":"Abraham","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2013.04.017_bib37","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1172\/JCI114844","article-title":"An insertion\/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels","volume":"86","author":"Rigat","year":"1990","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.cjca.2013.04.017_bib38","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.2217\/pgs.10.124","article-title":"Pharmacogenomic testing for angiotensin-converting enzyme inhibitors: getting ready for prime time","volume":"11","author":"de Denus","year":"2010","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.cjca.2013.04.017_bib39","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s11010-011-1115-8","article-title":"Association of angiotensin-converting enzyme I\/D polymorphism with heart failure: a meta-analysis","volume":"361","author":"Bai","year":"2012","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.cjca.2013.04.017_bib40","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1001\/archinte.168.10.1077","article-title":"Angiotensin-converting enzyme insertion\/deletion gene polymorphic variant as a marker of coronary artery disease: a meta-analysis","volume":"168","author":"Zintzaras","year":"2008","journal-title":"Arch Int Med"},{"key":"10.1016\/j.cjca.2013.04.017_bib41","first-page":"252","article-title":"Genetic polymorphism, medical therapy and sequential cardiac function in patients with heart failure","volume":"90","author":"Cuoco","year":"2008","journal-title":"Arq Bras Cardiol"},{"key":"10.1016\/j.cjca.2013.04.017_bib42","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1016\/j.jacc.2004.08.048","article-title":"Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure","volume":"44","author":"McNamara","year":"2004","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2013.04.017_bib43","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1161\/CIRCULATIONAHA.110.004341","article-title":"Renin-angiotensin-aldosterone genotype influences ventricular remodeling in infants with single ventricle","volume":"123","author":"Mital","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2013.04.017_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1592\/phco.30.1.1","article-title":"Association of aldosterone concentration and mineralocorticoid receptor genotype with potassium response to spironolactone in patients with heart failure","volume":"30","author":"Cavallari","year":"2010","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.cjca.2013.04.017_bib45","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.amjcard.2007.02.097","article-title":"Usefulness of the aldosterone synthase gene polymorphism C-344-T to predict cardiac remodeling in African-Americans versus non-African-Americans with chronic systolic heart failure","volume":"100","author":"Biolo","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjca.2013.04.017_bib46","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.amjmed.2003.12.033","article-title":"Effects of ACE gene insertion\/deletion polymorphism on response to spironolactone in patients with chronic heart failure","volume":"116","author":"Cicoira","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.cjca.2013.04.017_bib47","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.jacc.2006.07.030","article-title":"Aldosterone synthase promoter polymorphism predicts outcome in African Americans with heart failure: results from the A-HeFT Trial","volume":"48","author":"McNamara","year":"2006","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2013.04.017_bib48","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1345\/aph.1K657","article-title":"Effects of AGTR1 A1166C gene polymorphism in patients with heart failure treated with candesartan","volume":"42","author":"de Denus","year":"2008","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.cjca.2013.04.017_bib49","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1592\/phco.27.6.874","article-title":"Pharmacogenetics of beta-blockers","volume":"27","author":"Shin","year":"2007","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.cjca.2013.04.017_bib50","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S1388-9842(03)00044-8","article-title":"An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study","volume":"5","author":"White","year":"2003","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cjca.2013.04.017_bib51","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.jacc.2008.05.022","article-title":"Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol","volume":"52","author":"Sehnert","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2013.04.017_bib52","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jacc.2012.03.023","article-title":"Relationship of beta-blocker dose with outcomes in ambulatory heart failure patients with systolic dysfunction: results from the HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) trial","volume":"60","author":"Fiuzat","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2013.04.017_bib53","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1038\/nm930","article-title":"Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure","volume":"9","author":"Mialet Perez","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.cjca.2013.04.017_bib54","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/FPC.0b013e3280105245","article-title":"Synergistic polymorphisms of beta1 and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failure","volume":"17","author":"Lobmeyer","year":"2007","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.cjca.2013.04.017_bib55","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1097\/FPC.0b013e3282ef7354","article-title":"Arg389Gly-beta1-adrenergic receptors determine improvement in left ventricular systolic function in nonischemic cardiomyopathy patients with heart failure after chronic treatment with carvedilol","volume":"17","author":"Chen","year":"2007","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.cjca.2013.04.017_bib56","doi-asserted-by":"crossref","first-page":"11288","DOI":"10.1073\/pnas.0509937103","article-title":"A\u00a0polymorphism within a conserved beta1-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure","volume":"103","author":"Liggett","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cjca.2013.04.017_bib57","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1161\/01.CIR.0000141297.50027.A4","article-title":"Effect of baseline or changes in adrenergic activity on clinical outcomes in the beta-blocker evaluation of survival trial","volume":"110","author":"Bristow","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2013.04.017_bib58","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1161\/CIRCHEARTFAILURE.109.885962","article-title":"An alpha2C-adrenergic receptor polymorphism alters the norepinephrine-lowering effects and therapeutic response of the beta-blocker bucindolol in chronic heart failure","volume":"3","author":"Bristow","year":"2010","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cjca.2013.04.017_bib59","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S1388-9842(03)00163-6","article-title":"Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON)","volume":"5","author":"Cohn","year":"2003","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cjca.2013.04.017_bib60","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/clpt.2011.34","article-title":"Pharmacogenetics: from bench to byte\u2013an update of guidelines","volume":"89","author":"Swen","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cjca.2013.04.017_bib61","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/01.fjc.0000184117.76188.68","article-title":"Influence of CYP2D6 genotype on metoprolol plasma concentration and beta-adrenergic inhibition during long-term treatment: a comparison with bisoprolol","volume":"46","author":"Nozawa","year":"2005","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"key":"10.1016\/j.cjca.2013.04.017_bib62","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/00008571-200208000-00007","article-title":"Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment","volume":"12","author":"Rau","year":"2002","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.cjca.2013.04.017_bib63","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1067\/mcp.2002.127111","article-title":"Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects","volume":"72","author":"Wuttke","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cjca.2013.04.017_bib64","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/clpt.2008.218","article-title":"Impact of the CYP2D6 genotype on the clinical effects of metoprolol: a prospective longitudinal study","volume":"85","author":"Rau","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cjca.2013.04.017_bib65","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s00228-011-1130-4","article-title":"Feasibility of pharmacy-initiated pharmacogenetic screening for CYP2D6 and CYP2C19","volume":"68","author":"Swen","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.cjca.2013.04.017_bib66","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1001\/jama.298.10.1171","article-title":"Carvedilol for children and adolescents with heart failure: a randomized controlled trial","volume":"298","author":"Shaddy","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2013.04.017_bib67","doi-asserted-by":"crossref","first-page":"900","DOI":"10.3109\/02770900903199961","article-title":"Polymorphism of the ADRB2 gene and response to inhaled beta- agonists in children with asthma: a meta-analysis","volume":"46","author":"Finkelstein","year":"2009","journal-title":"J\u00a0Asthma"},{"key":"10.1016\/j.cjca.2013.04.017_bib68","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1097\/PCC.0b013e318184985b","article-title":"Single nucleotide polymorphisms in genes of circulatory homeostasis in surviving pediatric intensive care patients with meningococcal infection","volume":"9","author":"Bunker-Wiersma","year":"2008","journal-title":"Pediatr Crit Care Med"},{"key":"10.1016\/j.cjca.2013.04.017_bib69","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/sj.clpt.6100131","article-title":"Genetic variation in the renal sodium transporters NKCC2, NCC, and ENaC in relation to the effects of loop diuretic drugs","volume":"82","author":"Vormfelde","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cjca.2013.04.017_bib70","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/sj.clpt.6100404","article-title":"The polymorphisms Asn130Asp and Val174Ala in OATP1B1 and the CYP2C9 allele *3 independently affect torsemide pharmacokinetics and pharmacodynamics","volume":"83","author":"Vormfelde","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cjca.2013.04.017_bib71","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1365-2125.2005.02392.x","article-title":"Meta-analysis of the influence of MDR1 C3435T polymorphism on digoxin pharmacokinetics and MDR1 gene expression","volume":"60","author":"Chowbay","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.cjca.2013.04.017_bib72","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/j.jacc.2009.02.027","article-title":"Recipient genotype is a predictor of allograft cytokine expression and outcomes after pediatric cardiac transplantation","volume":"53","author":"Auerbach","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2013.04.017_bib73","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1097\/TP.0b013e31821c1e10","article-title":"Gene polymorphisms impact the risk of rejection with hemodynamic compromise: a multicenter study","volume":"91","author":"Girnita","year":"2011","journal-title":"Transplantation"},{"key":"10.1016\/j.cjca.2013.04.017_bib74","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1097\/TP.0b013e3181722edc","article-title":"Genetic polymorphisms impact the risk of acute rejection in pediatric heart transplantation: a multi-institutional study","volume":"85","author":"Girnita","year":"2008","journal-title":"Transplantation"},{"key":"10.1016\/j.cjca.2013.04.017_bib75","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s00228-012-1330-6","article-title":"Population pharmacokinetics and pharmacogenetics of once daily prolonged-release formulation of tacrolimus in pediatric and adolescent kidney transplant recipients","volume":"69","author":"Zhao","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.cjca.2013.04.017_bib76","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/j.healun.2011.08.001","article-title":"Age and CYP3A5 genotype affect tacrolimus dosing requirements after transplant in pediatric heart recipients","volume":"30","author":"Gijsen","year":"2011","journal-title":"J\u00a0Heart Lung Transplant"},{"key":"10.1016\/j.cjca.2013.04.017_bib77","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2217\/pgs.09.177","article-title":"Update on the clinical pharmacogenomics of organ transplantation","volume":"11","author":"Burckart","year":"2010","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.cjca.2013.04.017_bib78","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/j.1399-0012.2009.01198.x","article-title":"The role of CYP3A5 genotypes in dose requirements of tacrolimus and everolimus after heart transplantation","volume":"25","author":"Kniepeiss","year":"2011","journal-title":"Clin Transplant"},{"key":"10.1016\/j.cjca.2013.04.017_bib79","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1177\/0091270003262108","article-title":"Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism","volume":"44","author":"Zheng","year":"2004","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.cjca.2013.04.017_bib80","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/86882","article-title":"Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression","volume":"27","author":"Kuehl","year":"2001","journal-title":"Nat Genet"},{"key":"10.1016\/j.cjca.2013.04.017_bib81","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/S0026-895X(25)09155-2","article-title":"Bimodal distribution of renal cytochrome P450 3A activity in humans","volume":"50","author":"Haehner","year":"1996","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.cjca.2013.04.017_bib82","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1016\/j.bcp.2004.07.012","article-title":"In\u00a0vitro metabolism of cyclosporine A by human kidney CYP3A5","volume":"68","author":"Dai","year":"2004","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.cjca.2013.04.017_bib83","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.pharmthera.2006.04.006","article-title":"An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients","volume":"112","author":"Masuda","year":"2006","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.cjca.2013.04.017_bib84","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.clpt.2005.09.013","article-title":"Intestinal MDR1\/ABCB1 level at surgery as a risk factor of acute cellular rejection in living-donor liver transplant patients","volume":"79","author":"Masuda","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cjca.2013.04.017_bib85","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/01.fpc.0000114747.08559.49","article-title":"CYP3A5*1-carrying graft liver reduces the concentration\/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation","volume":"14","author":"Goto","year":"2004","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.cjca.2013.04.017_bib86","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1124\/mol.62.1.162","article-title":"Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism","volume":"62","author":"Lin","year":"2002","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.cjca.2013.04.017_bib87","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/TP.0b013e318200e991","article-title":"Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney transplant consortium","volume":"91","author":"Jacobson","year":"2011","journal-title":"Transplantation"},{"key":"10.1016\/j.cjca.2013.04.017_bib88","first-page":"721","article-title":"Optimization of initial tacrolimus dose using pharmacogenetic testing","volume":"87","author":"Thervet","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cjca.2013.04.017_bib89","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.healun.2012.05.010","article-title":"Renal function and genetic polymorphisms in pediatric heart transplant recipients","volume":"31","author":"Feingold","year":"2012","journal-title":"J\u00a0Heart Lung Transplant"},{"key":"10.1016\/j.cjca.2013.04.017_bib90","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.healun.2008.04.001","article-title":"No association between single nucleotide polymorphisms and the development of nephrotoxicity after orthotopic heart transplantation","volume":"27","author":"Klauke","year":"2008","journal-title":"J\u00a0Heart Lung Transplant"},{"key":"10.1016\/j.cjca.2013.04.017_bib91","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1097\/FPC.0b013e3283557c74","article-title":"The effect of CYP3A5 6986A>G and ABCB1 3435C>T on tacrolimus dose-adjusted trough levels and acute rejection rates in renal transplant patients: a systematic review and meta-analysis","volume":"22","author":"Terrazzino","year":"2012","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.cjca.2013.04.017_bib92","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/FPC.0b013e32834a48ca","article-title":"Lower tacrolimus daily dose requirements and acute rejection rates in the CYP3A5 nonexpressers than expressers","volume":"21","author":"Tang","year":"2011","journal-title":"Pharmacogenet Genomics"}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X13002535?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X13002535?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:39:01Z","timestamp":1760107141000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X13002535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":92,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["S0828282X13002535"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2013.04.017","relation":{},"ISSN":["0828-282X"],"issn-type":[{"type":"print","value":"0828-282X"}],"subject":[],"published":{"date-parts":[[2013,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacogenomics and Heart Failure in Congenital Heart Disease","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjca.2013.04.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}